ZENTEK LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.45 CAD | -3.97% |
|
-3.33% | 0.00% |
| Apr. 03 | Zentek Ltd. Enters into Definitive Distribution Agreement with Medwell Solutions LLC | CI |
| Mar. 25 | Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial | MT |
| Sales 2022 | 0.35 0.47 | Sales 2023 | 0.07 0.1 | Capitalization | 206M 282M |
|---|---|---|---|---|---|
| Net income 2022 | -38M -51.99M | Net income 2023 | -14M -19.15M | EV / Sales 2022 | 1,031,593,065 x |
| Net cash position 2022 | 24.44M 33.44M | Net cash position 2023 | 8.75M 11.96M | EV / Sales 2023 | 2,707,984,696 x |
| P/E ratio 2022 |
-9.19
x | P/E ratio 2023 |
-14.3
x | Employees | 29 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.07% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.58% | ||
| 1 week | -0.66% | ||
| Current month | -6.79% | ||
| 1 month | -11.18% | ||
| 3 months | -3.82% | ||
| 6 months | -15.17% | ||
| Current year | +4.14% |
1 week
1.38
1.59
1 month
1.381.69
Current year
1.382.12
1 year
1.302.30
3 years
1.307.50
5 years
0.007.50
10 years
0.007.50
| Managers | Title | Age | Since |
|---|---|---|---|
Gregory Fenton
CEO | Chief Executive Officer | - | 18-07-10 |
Wendy Ford
DFI | Director of Finance/CFO | - | 22-05-15 |
Adam MacIntosh
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ilse Treurnicht
BRD | Director/Board Member | - | 22-07-04 |
John Snisarenko
BRD | Director/Board Member | 61 | 23-10-04 |
Francis Dubé
COO | Chief Operating Officer | - | 18-05-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.45 | -3.97% | 41 330 |
| 24-04-24 | 1.51 | -2.58% | 34,610 |
| 24-04-23 | 1.55 | 0.00% | 29,919 |
| 24-04-22 | 1.55 | +9.15% | 137,727 |
| 24-04-19 | 1.42 | -5.33% | 111,109 |
Delayed Quote Toronto S.E., April 24, 2024 at 03:59 pm EDT
More quotes
Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Companyâs developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.
Calendar
2024-08-28
- Q1 2025 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.14% | 111M | |
| +4.09% | 43.84B | |
| +46.73% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- ZEN Stock
